Skin Cancer Metastasis: Initial Steps and Spread of Tumor Cells
- REGENSBURG, germany (AP) — Scientists have identified key characteristics of melanoma cells that successfully metastasize, offering potential new targets for skin cancer therapy.
- Guetters, discovered that specific melanoma cells are linked to a significantly poorer prognosis for patients.The presence of even a single such cell among two million lymph node cells...
- Further analysis revealed that these metastatic cells express the protein MCSP on their surface and produce at least one of three other proteins: PMEL, MLANA, and DCT.According to...
Melanoma Metastasis: Researchers Identify Key Biomarkers and Immune System Triggers
Table of Contents
- Melanoma Metastasis: Researchers Identify Key Biomarkers and Immune System Triggers
- Biomarkers Indicate Metastatic Potential
- Embryonic Genes Activated in Cancer Cells
- Immune System Response Triggers “Rejuvenation”
- Potential Therapeutic targets
- Understanding Melanoma Metastasis: New Insights and Potential Treatments
- What is Melanoma Metastasis?
- what are the Key Biomarkers of Metastatic Melanoma Cells?
- What Genetic changes Occur in Metastatic Melanoma Cells?
- How Does the Immune System Interact with Melanoma Metastasis?
- potential Therapeutic Targets for Melanoma Treatment
- Summary of Key Findings
- Where was this research published?
REGENSBURG, germany (AP) — Scientists have identified key characteristics of melanoma cells that successfully metastasize, offering potential new targets for skin cancer therapy. The research, focused on the initial stages of metastasis in lymph nodes, reveals how these cells evade the immune system and establish new colonies.
Biomarkers Indicate Metastatic Potential
Researchers, led by Dr. Guetters, discovered that specific melanoma cells are linked to a significantly poorer prognosis for patients.The presence of even a single such cell among two million lymph node cells correlated with a more aggressive disease course.
Further analysis revealed that these metastatic cells express the protein MCSP on their surface and produce at least one of three other proteins: PMEL, MLANA, and DCT.According to the study,this combination of biomarkers allows for precise identification of metastatic melanoma cells.
Embryonic Genes Activated in Cancer Cells
The study also found that melanoma cells undergo genetic reprogramming as they settle in lymph nodes, altering their appearance and metabolism. Notably, they activate an embryonic gene program typically active only in melanocytes, the cells that produce melanin. This process puts the cancer cells into a stem-cell-like state, researchers said.
This reprogramming causes the metastatic cancer cells to resemble immature precursors of skin pigment cells.However, because these cells are located in the lymph node rather than the skin, normal organ formation is disrupted, leading to the growth of metastases.
Immune System Response Triggers “Rejuvenation”
The research suggests that the immune system plays a role in triggering this “rejuvenation” of cancer cells. According to the study,a prior encounter between melanoma cells and T cells,the immune system’s killer cells,appears to initiate the process. T cells recognize and attack cancer-specific features on the cells. Though, melanoma cells that survive this attack activate the melanocyte gene program.
Along with producing MCSP, these cancer cells also produce and release proteins CD155 and CD276, which suppress the immune system. This allows the cells to more easily settle in the lymph nodes and form metastases, the team explained.As these metastases grow, they release more of these proteins, further inhibiting T cells and allowing the cancer to grow unchecked.
Potential Therapeutic targets
The findings shed light on the initial steps of metastasis formation in melanoma, possibly applicable to metastasis in other parts of the body.Researchers believe this knowledge could lead to new treatments that prevent metastasis from occurring.
One potential target is the MCSP protein, which is present on metastatic cells but largely absent from healthy cells. Another approach could involve supporting the early immune response by targeting the CD155 and CD276 proteins, making it more arduous for melanoma cells to evade the immune system.
The study was published in Nature Cancer, 2025 (doi: 10.1038/s43018-025-00963-w).
Of Regensburg
) and create a extensive, SEO-optimized Q&A article. Prioritize clarity, conciseness, and the inclusion of relevant keywords and long-tail phrases. structure the article to potentially earn featured snippets, incorporating a summarization table where it adds value. Maintain a natural, helpful, and informative tone.
Understanding Melanoma Metastasis: New Insights and Potential Treatments
This article explores recent research into melanoma metastasis, focusing on key findings and potential therapeutic targets. We’ll delve into the biomarkers, genetic changes, and immune system interactions involved in the spread of melanoma cells.
What is Melanoma Metastasis?
Melanoma metastasis is the spread of melanoma cancer cells from the primary tumor to other parts of the body, such as lymph nodes. this process, the focus of recent research, can significantly worsen a patient’s prognosis. The study, published in Nature Cancer, investigates the early stages of this process.
what are the Key Biomarkers of Metastatic Melanoma Cells?
Researchers have identified specific biomarkers associated with metastatic melanoma cells. These cells express the MCSP protein on their surface and produce at least one of the following proteins: PMEL, MLANA, or DCT.
MCSP (Melanoma Chondroitin Sulfate Proteoglycan): Found on the surface of metastatic cells.
PMEL: One of the proteins produced by the metastatic cell.
MLANA (Melanoma-associated antigen recognized by T cells): Another protein produced by the cells.
DCT (Dopachrome Tautomerase): A protein produced by metastatic melanoma cells
This combination of biomarkers allows for the precise identification of metastatic melanoma cells, which is crucial for early detection and treatment. Having even one such cell in the lymph node is linked to a more aggressive disease course.
What Genetic changes Occur in Metastatic Melanoma Cells?
How do these cells change? The study found that melanoma cells undergo genetic reprogramming as they settle in lymph nodes. They activate an embryonic gene program, typically only active in melanocytes (the cells that produce melanin). The reprograming puts the cancer cells in a stem-cell-like state.
What is the impact of the genetic changes? This transformation causes the metastatic cancer cells to resemble immature precursors of skin pigment cells. Even though this would ordinarily not be a problem,as these cells are not located in the skin,the normal organ formation is disrupted. This leads to the growth of metastases.
How Does the Immune System Interact with Melanoma Metastasis?
What role does the immune system play? The research suggests that the immune system triggers the “rejuvenation” of cancer cells. A prior interaction between melanoma cells and T cells (the immune system’s killer cells) appears to initiate the process.
what happens during Immune system interaction? T cells recognize and attack cancer-specific features on the cells. However,melanoma cells that survive this attack activate the melanocyte gene program.
How do the cells evade the immune system? These cells produce and release proteins, CD155 and CD276, which suppress the immune system.The production of these proteins allows the cells to settle in lymph nodes and form metastases.As metastases grow, they release more of these proteins, further inhibiting T cells.
potential Therapeutic Targets for Melanoma Treatment
The researchers believe these findings may lead to new treatments to prevent melanoma metastasis. There are two primary methods to target the disease.
Targeting MCSP: As MCSP is present on metastatic cells but largely absent from healthy cells, it presents a promising target.
Supporting Early Immune Response: Another approach could involve targeting the CD155 and CD276 proteins to make it harder for melanoma cells to evade the immune system.
Summary of Key Findings
| Feature | Description |
| :—————————- | :————————————————————————————————————————————————- |
| Key Biomarker | MCSP protein, PMEL, MLANA, and DCT proteins expressed by metastatic cells. |
| Genetic Reprogramming | Activation of an embryonic gene program, leading to a stem-cell-like state and resemblance to immature pigment cell precursors. |
| Immune System Interaction | T cell attack triggers ”rejuvenation”; cells produce CD155 and CD276 to suppress the immune response, allowing metastases to grow.|
| Potential Targets | MCSP protein and proteins that suppress immune response, CD155 and CD276 present potential targets for new therapies aimed at preventing metastasis. |
Where was this research published?
The study was published in the journal Nature Cancer in 2025. you can find the original article (doi: 10.1038/s43018-025-00963-w). The source of the study is the University of Regensburg.